

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE

02 AUG 14 PM 3:27

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Ropes & Gray			
2. Address <input type="checkbox"/> Check if different than previously reported 1301 K Street, N.W., Suite 800 East, Washington, D.C. 20005			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Thomas M. Susman	Telephone (202) 626-3920	E-mail (optional) tsusman@ropesgray.com	5. Senate ID #
7. Client Name <input type="checkbox"/> Self Aventis Pharmaceuticals			6. House ID # 3072

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-Dec)
9. Check if this filing amends a previously filed version of this report 10. Check if this is a Termination Report ⇒ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13**12. Lobbying Firms**

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000 \$10,000 or more ⇒ \$ 40,000.00
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000 \$10,000 or more ⇒ \$ _____
Expenses (nearest \$20,000)**14. REPORTING METHOD.** Check box to indicate accounting method. See instructions for description of Method A. Reporting amounts using LDA definition Method B. Reporting amounts under section 6013(b)(3) Internal Revenue Code Method C. Reporting amounts under section 162(e)(1)(B) Internal Revenue Code

Signature _____

Printed Name and Title _____

Thomas M. Susman, Partner

Registrant Name Ropes & Gray Client Name Aventis Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific lobbying issues

Hatch-Waxman Act
Drug Competition Act of 2001
S. 754


17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Thomas M. Susman	
James Spears	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8-14-02

Printed Name and Title Thomas M. Susman, Partner

I

Registrant Name Ropes & Gray Client Name Aventis Pharmaceuticals

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

Hatch-Waxman Act
Drug Competition Act of 2001
S. 754


17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Thomas M. Susman	
James Spears	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/14/02

Printed Name and Title Thomas M. Susman, Partner

